sotorasib


( Last Updated : July 21, 2022)
Generic Name:
sotorasib
Project Status:
Pending
Therapeutic Area:
KRAS G12C-mutated advanced NSCLC
Manufacturer:
Amgen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Lumakras
Project Line:
Reimbursement Review
Project Number:
PC0300-000
Call for patient/clinician input closed:
Tumour Type:
Lung

Details


Manufacturer Requested Reimbursement Criteria1:
Treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.
Date NOC Issued:
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.